SCHEMBL20914299

SCHEMBL20914299

Cc1[nH]c2c(-c3ccccc3)c(C#N)nn2c(=O)c1-c1nc2c(N(C)C)cccc2o1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MEN1 O00255 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ PDGFRA P16234 1/20 0.31
▸ MAPK8 P45983 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ CLK4 Q9HAZ1 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ GRM5 P41594 1/20 0.30
▸ MDM2 Q00987 1/20 0.30
▸ MAT2A P31153 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837038 0.88 ADORA2A (0.34) CYP1A2KDM4EALDH1A1HSD17B10MEN1
SCHEMBL20913968 0.88 KDM4E (0.34) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20914077 0.86 TNKS (0.37) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20913931 0.86 KMT2A (0.35) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20914080 0.86 KMT2A (0.32) CYP1A2KDM4EALDH1A1MEN1CYP2C9
SCHEMBL20837037 0.85 P2RY6 (0.37) CYP1A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20914097 0.84 POLB (0.37) KDM4EALDH1A1MEN1KMT2APDGFRA
SCHEMBL20914221 0.83 HTR3A (0.31) CYP1A2MEN1CYP2C9PKMTSHR
SCHEMBL20914308 0.81 MAT2A (0.34) CYP1A2KDM4EMEN1CYP2C9PKM
SCHEMBL20914241 0.79 MEN1 (0.42) CYP1A2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 CYP1A2 1015/4885KDM4E 1922/4885ALDH1A1 1246/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 CYP1A2 1015/4885KDM4E 1922/4885ALDH1A1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback